Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series - 14/11/16
, Jurr Boer, MD, PhD b, Errol P. Prens, MD, PhD c, Ditte M.L. Saunte, MD, PhD a, Inge E. Deckers, MD, PhD c, Lennart Emtestam, MD, PhD d, Karin Sartorius, MD, PhD e, Gregor B.E. Jemec, MD, DMSc aAbstract |
Background |
Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle. Standard practice of managing acute flares with corticosteroid injection lacks scientific evidence.
Objective |
We sought to assess the outcomes of routine treatment using intralesional triamcinolone (triamcinolone acetonide 10 mg/mL) in the management of acute flares in HS.
Methods |
This was a prospective case series evaluating the effect of intralesional corticosteroids for alleviation of acute flares in HS. Physician- and patient-reported outcomes were noted.
Results |
Significant reductions in physician-assessed erythema (median score from 2-1, P < .0001), edema (median score from 2-1, P < .0001), suppuration (median score from 2-1, P < .0001), and size (median score from 3-1, P < .0001) was demonstrated at follow-up. A significant difference in patient-reported pain visual analog scale scores occurred after 1 day (from 5.5-2.3, P < .005) and from day 1 to day 2 (from 2.3-1.4, P < .002).
Limitations |
Small study size, open single-arm design, and short follow-up time are the limitations of this study.
Conclusion |
Intralesional injection of corticosteroids is perceived as beneficial by physicians and patients in the management of HS flares by reducing pain after 1 day and signs of inflammation approximately 7 days later.
Le texte complet de cet article est disponible en PDF.Key words : acne inversa, corticosteroids, hidradenitis suppurativa, inflammation, intralesional, skin disease, triamcinolone acetonide
Plan
| Drs Boer and Prens contributed equally. |
|
| Funding sources: None. |
|
| Disclosure: Dr Boer serves on the advisory board of AbbVie. Dr Saunte was paid as a consultant for advisory board meetings by AbbVie and as a speaker for Bayer, Galderma, Astellas, and Leo Pharma. She also received reimbursement of travel expenses from Galderma, Pfizer, AbbVie, and Desitin. Dr Prens received honoraria from AbbVie, Amgen, Celgene, Janssen, Galderma, Novartis, and Pfizer for participation as a speaker and advisory board member, and received investigator-initiated grants (paid to Erasmus University Medical Center) from AbbVie, AstraZeneca, Janssen, and Pfizer. Dr Emtestam was paid as a consultant by AbbVie, as a consultant for advisory board meetings by AbbVie, and as a speaker for Novartis and AbbVie. Dr Sartorius received honoraria from AbbVie (consultant/faculty meeting) and Leo Pharma (investigator/faculty meeting), and honoraria paid to the department by AbbVie. Dr Jemec received honoraria from AbbVie, MSD, and Pfizer for participation on advisory boards, and grants from AbbVie, Actelion, Janssen-Cilag, Leo Pharma, Novartis, and Regeneron for participation as an investigator. He received speaker honoraria from AbbVie, Galderma, Leo Pharma, and MSD. He has furthermore received unrestricted research grants from AbbVie and Leo Pharma. Drs Riis and Deckers have no conflicts of interest to declare. |
Vol 75 - N° 6
P. 1151-1155 - décembre 2016 Retour au numéro
Article précédent
- Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (GP): A retrospective cohort study
- John S. Barbieri, Ole Hoffstad, David J. Margolis
- Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials
- Alexandra B. Kimball, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Enkeleida Nikaï, Baojin Zhu, Emily Edson-Heredia, Hilde Carlier, Chen-Yen Lin, Orin Goldblum, Gil Yosipovitch
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?